Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
April 25, 2025
First-in-class program is in late lead optimization Parabilis Medicines , a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, is presenting